Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2019 - 2020)
Phathom Pharmaceuticals (PHAT) posted quarterly Gains from Investment Securities of -$95000.0 for Q1 2020, down 100.26% quarter-over-quarter from $37.2 million in Q4 2019.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Gains from Investment Securities (2019 - 2020) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Gains from Investment Securities for 2 consecutive years, with -$95000.0 the latest figure, recorded in Q1 2020.
- In Q1 2020, Gains from Investment Securities changed N/A year-over-year to -$95000.0; the TTM figure through Dec 2020 stood at -$95000.0 (changed N/A YoY), while the FY2020 annual figure was -$95000.0, down 100.1% from the prior year.
- Gains from Investment Securities eased to -$95000.0 in Q1 2020 per PHAT's latest filing, from $37.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $57.8 million in Q3 2019 and bottomed at -$95000.0 in Q1 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -95,000.00 |
| Dec 31, 2019 | 37.21 Mn |
| Sep 30, 2019 | 57.78 Mn |
| Jun 30, 2019 | 1.28 Mn |